- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07638943
Refitting Satisfied INFUSE One-Day Multifocal Wearers to DAILIES TOTAL1 Multifocal Contact Lenses (INFUSETODT1)
Clinical Outcomes Following Refit From INFUSE One-Day Multifocal to DAILIES TOTAL1 Multifocal in Satisfied Presbyopic Wearers: A Prospective, Open-Label, Single-Arm Study
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: David Geffen, OD, FAAO
- Phone Number: 8584556800
- Email: dgeffen@gwsvision.com
Study Locations
-
-
California
-
La Jolla, California, United States, 92037
- Recruiting
- Gordon Schanzlin New Vision Institute
-
Contact:
- David Geffen, OD, FAAO
- Phone Number: 858-455-6800
- Email: dgeffen@gwsvision.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Age ≥40 years at enrollment Current satisfied wearer of Bausch + Lomb INFUSE One-Day Multifocal (kalifilcon A) in both eyes; Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) score <12 at baseline Minimum contact lens wear of ≥8 hours/day, ≥5 days/week, for ≥30 days prior to Visit 1 Best-corrected distance visual acuity ≥20/25 (0.18 LogMAR) or better in each eye Manifest refraction within study lens parameters (Sphere: +6.00 D to -10.00 D; Add: Low, Medium, High) Willing to wear DAILIES TOTAL1 Multifocal lenses for ≥8 hours/day, ≥5 days/week and complete all study questionnaires Able to provide written informed consent and comply with investigator instructions
Exclusion Criteria:
Active ocular infection, inflammation, or clinically significant ocular surface disease (e.g., severe dry eye, pterygium, keratoconus) Uncontrolled systemic disease or use of systemic medications known to significantly affect the tear film, unless on a stable dose for ≥90 days History of refractive surgery (LASIK, PRK, RK) or intraocular surgery (cataract or IOL implantation) Clinically significant ectropion, entropion, or trichiasis Baseline corneal fluorescein staining score >2 in any single zone (NEI/Industry scale) Current monovision or modified monovision contact lens wear Pregnant or lactating participants Participation in another clinical trial within 30 days prior to enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: DAILIES TOTAL1 Multifocal
Participants currently wearing INFUSE One-Day Multifocal (kalifilcon A) are refit into DAILIES TOTAL1 Multifocal (delefilcon A) daily disposable contact lenses and followed for approximately 3 weeks.
|
Daily disposable multifocal contact lens refit to match the participant's habitual INFUSE One-Day Multifocal power and add level.
Worn a minimum of 8 hours/day, at least 5 days/week for approximately 3 weeks.
A mandatory ~15-minute equilibration period is required before over-refraction at the fitting visit.
Power is finalized at Visit 2 if adjustment is needed; the primary endpoint is assessed after 2 weeks on the finalized prescription.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of participants with Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) score <12
Time Frame: 2 weeks after wearing finalized DAILIES TOTAL1 Multifocal prescription (Visit 3, ~Day 21)
|
The Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) is an 8-item validated questionnaire assessing the frequency and intensity of contact lens-related dryness and discomfort. Total scores range from 0 to 37, with higher scores indicating greater dryness and discomfort (worse symptoms). A score of less than 12 indicates asymptomatic status. The primary endpoint is the proportion of participants achieving a CLDEQ-8 score <12 after 2 weeks on their finalized DAILIES TOTAL1 Multifocal prescription. Results will be reported with exact (Clopper-Pearson) 95% confidence intervals. |
2 weeks after wearing finalized DAILIES TOTAL1 Multifocal prescription (Visit 3, ~Day 21)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GSNVI-INFUSETODT1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Presbyopia
-
Ohio State UniversityRecruitingPresbyopia | Presbyopia CorrectionUnited States
-
Bruno Vision Careiuvo BioScience Operations, LLCCompleted
-
Johnson & Johnson Vision Care, Inc.CompletedPresbyopia CorrectionUnited Kingdom
-
VIS, Inc.Active, not recruitingPresbyopia Correction
-
AST Products, Inc.CompletedCataract | Presbyopia CorrectionSpain
-
IROC AGAMO IrelandActive, not recruitingCataract | Presbyopia CorrectionSwitzerland
-
Bausch & Lomb IncorporatedCompletedMyopia and Hyperopia and PresbyopiaUnited States
-
Technolas Perfect Vision GmbHUnknownHyperopic PresbyopiaIreland
-
The Hong Kong Polytechnic UniversityNot yet recruitingPresbyopia | Presbyopia Correction
-
University Eye Hospital SvjetlostCompletedCataract | Visual Acuity | Presbyopia CorrectionCroatia
Clinical Trials on DAILIES TOTAL1 Multifocal (delefilcon A)
-
Alcon ResearchTerminatedPresbyopia | Astigmatism | Myopia | HyperopiaUnited States
-
Alcon, a Novartis CompanyCompletedRefractive Error
-
Alcon, a Novartis CompanyCompletedRefractive ErrorUnited States
-
Alcon ResearchCompletedRefractive ErrorsUnited States
-
University of WaterlooAlcon ResearchCompleted
-
Alcon ResearchCompletedRefractive Error
-
Alcon ResearchCompletedRefractive Errors | PresbyopiaUnited States, Canada, United Kingdom
-
University of WaterlooAlcon ResearchCompleted
-
CooperVision, Inc.Completed